• L Gaigne, C Piperoglou, N Banzet, L Ghellab, F Vély, N Schleinitz, and M Ebbo.
• Département de médecine interne, hôpital La Timone, CHU de Timone, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, Marseille, France. Electronic address: lea.gaigne@gmail.com.
• Rev Med Interne. 2022 Sep 1; 43 (9): 528-536.

AbstractAnti-cytokine antibodies (ACA) are an emerging cause of acquired immunodeficiency, especially in previously healthy adults. The most frequently reported are anti-IFN-γ responsible for disseminated non-tuberculous mycobacteria infections, and anti-GM-CSF mainly in mycobacteria, cryptococcosis and nocardiosis infections. The presence of anti-IFN-α in severe COVID-19 infections has recently been described. The search for and detection of these ACAs in an unusual infection situation makes it possible to set up specific therapies in addition to the anti-infective treatment. ACAs are also frequent in various autoimmune pathologies where, in addition to being indicators of the breakdown of immune tolerance, they can modulate the activity of the disease according to their cytokine target. In this review of the literature, we will focus on the epidemiology and the clinical impact of these ACAs in healthy subjects and in infectious or dysimmune diseases.Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

14 keywords...

hide…